Reason for request
Inclusion
Clinical Benefit
| Substantial |
The actual benefit provided by LOJUXTA in combination with other lipid lowering medicines is substantial in adult patients with homozygous familial hypercholesterolaemia (HoFH) uncontrolled by these lipid-lowering treatments used at maximum doses, whether or not combined with apheresis. |
Clinical Added Value
| minor |
The addition of LOJUXTA to an optimal lipid-lowering therapy, used at maximum doses, whether or not combined with apheres is, in adult patients with uncontrolled homozygous familial hypercholesterolaemia (HoFH), provides a minor improvement in actual benefit (IABIV). |
eNq1mFFP2zAQx9/7KaK8NyHQAp3Soq2DrdLQOqDatBfkJlfqzNjhbLdln35OU0aZHDHc+jGx87+L7++fT07PVvcsWABKKng/TKKDMACeiZzyu344ublon4Zng1ZakAV5nnZo5kVJEgYZI1L2w2o0mgLhMvpx+eUjmO8Bw0ErSMW0gEy9mKcVZdFnIueXpKzmBOlC0Dy4BzUXeT8stVq/DVKp0GQxWAr8JUuSQRpv3myPFred7fdpXIn9h6qWgF8Iv7OKAnfSzDQicDUkCu4EPjbke+SkTeUVSKExgzFR8zGKBc0ht4aYESbBKchsmV8DLhioKohVPC6ye+kkTgqyuoKHkT3p92Z0qFaqfdBOTnrJ8clRr9vpdhKnULi1VPYqmJ+Is9vkJOl1Dk9j4DEThV4p4libsUBFmKeqUDl8aSxPcRAeXq1+TmXJyGNUyNJ1qQgSMwxotr+/H6n+4AYNkJhZs3/0uWYsfmPWkw0uPGVc0WgoNFcN1Jhcuy7EUHAFq+aKuoFOrTZepCD3J/tbcDvkx3rKaOaKNAMdDVJNrkbNRNsnDD4QCRP0R4PvlOdiKfdPme2qesq+XIPSKlpintwe9k6Pk27XeRP9NBZqOGHONYoSYsMfKnfByojPxK5AMa60Sz15cm92XPc5IiMMGjqdtiNbjA+fGjNvTve3i+oBq+in8xtXe3zTgI/X60erNM37fwvrBl4fNDdmbEz87daud7iXHlijnRxzpUr5Lo6Xy2U0J7ItiVmlaIZ7J/vWYeqvA/dyYtcdTE1HT6lP62PvbRVy3Wmvnem79qmb7zf9sDWGQg071KKGsjd0js73T+PnJtVb2uMX9PAXZt1QEkUF99Xo6KlVcTf+m7ryCzSA+Dqb0YYbkUZfpnF9GzNopXF1EzNo/QEjNuVK
YeH3mJ6h8CNrD0be
